Factory Location: Changzhou

Main Sales Markets: Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

Monthly Production Capacity: 1000kgs

Packaging Information: 25kgs

Delivery Lead Time: at once

Sample Provided: no

Payment Terms: L/C

Nirmatrelvir

2628280-40-8

Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CLPRO) inhibitor that is the subject of clinical trial NCT04756531. 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. 
Ritonavir
CAS 155213-67-5